^
Association details:
| Biomarker: | EGFR C797S + EGFR T790M + EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) + Qi Xinke (iruplinalkib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations
Published date:
06/20/2022
Excerpt:
WX-0593 and Vectibix showed a strong synergistic inhibitory effect on the proliferation of two EGFR triple-mutant Ba/F3 cell lines (EGFR L858R/T790M/C797S and Del19/T790M/C797S)….WX-0593 exhibited a synergetic effect with an EGFR monoclonal antibody on osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC) both in vitro and in vivo. Their combination showed potent antitumor efficacy and an acceptable safety profile, which may be a promising strategy for the treatment of patients with EGFR triple-mutant NSCLC...
DOI:
10.21037/atm-22-2780
Source:
Title:
5459 - Synergistic effects of WX-0593 in combination with panitumumab on osimertinib-resistant EGFR-mutantnon-small cell lung cancer in vitro and in vivo
Published date:
03/09/2022
Excerpt:
The tumor cell inhibition rates of WX-0593 and panitumumab alone or combined were assessed in osimertinib-resistant cis EGFR triple-mutant cell lines, including PC9 (EGFR Del19/T790M/C797S), NCI-H1975 (EGFR L858R/T790M/C797S), Ba/F3 (EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S). The in vivo tumor suppressive efficacy of single-agent WX-0593, panitumumab, and their combination was evaluated in H1975 (EGFR del19/T790M/C797S) and Ba/F3 (EGFR L858R/T790M/C797S) cell line-derived xenograft (CDX) models of BALB/c nude mice...the combination of WX-0593 and panitumumab had a potent synergistic effect on proliferation inhibition in all the four cell lines with cis EGFR triple mutations resistant to osimertinib. WX-0593 and panitumumab alone had tumor suppressive effects in the Ba/F3 CDX model. The data from the study suggested that WX-0593 and panitumumab had a promising synergistic effect on osimertinib-resistant EGFR-mutant NSCLC both in vitro and in vivo.
